The Clinical Implementation Division, led by Prof Andrew Biankin, is predominantly focused on early drug development, from phase one clinical studies through to randomised phase two trials.
It drives and oversees national networks for clinical trials and contributes to similar networks led from other institutions.
Our researchers are working on cancer science that really matters in the real world.
Research Team